We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford Biomedica Announces Development Milestone in its Collaboration with Molmed
News

Oxford Biomedica Announces Development Milestone in its Collaboration with Molmed

Oxford Biomedica Announces Development Milestone in its Collaboration with Molmed
News

Oxford Biomedica Announces Development Milestone in its Collaboration with Molmed

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Biomedica Announces Development Milestone in its Collaboration with Molmed"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford BioMedica has announced that its partner MolMed has received regulatory approval to start a Phase III trial of TK therapy for high risk acute leukaemia.

Under a license agreement with Oxford BioMedica, MolMed’s TK therapy product employs Oxford BioMedica’s retroviral ex vivo gene delivery technology. The start of a Phase III trial of TK therapy triggers an undisclosed milestone payment to Oxford BioMedica.

Advertisement